Search

Displaying results 2611 - 2620 of 10000 in total
  1. Drug

    Estradiol cypionate

    go.drugbank.com/drugs/DB13954
    ApprovedVet approved

    in potency and in estrogenic effects. … [DB00783] is commonly produced with an ester side-chain as endogenous estradiol has very low oral bioavailability on its own (2-10%).

  2. Drug

    Raxibacumab

    go.drugbank.com/drugs/DB08902
    ApprovedInvestigational

    Raxibacumab is produced by recombinant DNA technology in a murine cell expression system. FDA approved on December 14, 2012.

  3. Drug

    Taletrectinib

    go.drugbank.com/drugs/DB18711
    ApprovedInvestigational

    [A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523] … Taletrectinib is an orally available small molecule kinase inhibitor.

  4. Drug

    Salsalate

    go.drugbank.com/drugs/DB01399
    ApprovedInvestigational

    Such capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours. … The usefulness of salicylic acid, the active in vivo product of salsalate, in the treatment of arthritic disorders has been established.

  5. Drug

    Alteplase

    go.drugbank.com/drugs/DB00009
    ApprovedInvestigational

    [L43125] It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. … [A252330,L43125] Alteplase is a purified glycoprotein of 527 amino acids expressed in Chinese hamster ovary (CHO) cells.

  6. Drug

    Hyaluronidase (human recombinant)

    go.drugbank.com/drugs/DB06205
    ApprovedInvestigational

    [A199047] Hyaluronidase was first used in prescription products in the United States on 5 May 2004.[L13338] … [L13338] The action of hyaluronidase was first described in 1936, and named in 1939.

  7. Drug

    Etacrynic acid

    go.drugbank.com/drugs/DB00903
    ApprovedInvestigational

    A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. … This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.

  8. Drug

    Peramivir

    go.drugbank.com/drugs/DB06614
    ApprovedInvestigational

    Peramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. … Being an influenza virus neuraminidase inhibitor, peramivir works by preventing new viruses from emerging from infected cells.

  9. Drug

    Landiolol

    go.drugbank.com/drugs/DB12212
    ApprovedInvestigational

    [A264733,A264738] First approved in Japan in 2002 [A264758] for the treatment of intraoperative tachyarrhythmias,[A264733] landiolol was approved in Canada in April 2024 [L51938] and in the US in November … [A264733] Compared to other beta-blockers, landiolol possesses unique pharmacodynamic and pharmacokinetic properties, in that it has a rapid onset and short duration of action, and has a greater affinity

  10. Drug

    Erlotinib

    go.drugbank.com/drugs/DB00530
    ApprovedInvestigational

    Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer … This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.